Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Oxford Nanopore Sues PacBio in Europe Alleging Infringement of Harvard IP

This article, originally published on April 21, has been updated with additional information from Oxford Nanopore Technologies.

NEW YORK (GenomeWeb) – Oxford Nanopore Technologies said today that it has initiated legal proceedings in Europe against Pacific Biosciences, alleging infringement of intellectual property from Harvard University for which Oxford holds an exclusive license.

The company filed one lawsuit in the Patents Court of the High Court's Chancery Division in the UK and another with a court in Mannheim, Germany.

The patent, EP 1192453, is entitled "Molecular and atomic scale evaluation of biopolymers" and lists Daniel Branton, Timothy Denison, and Jene Golovchenko as inventors.

Oxford Nanopore declined to comment further on the action at this time. PacBio also declined to comment.

PacBio filed a lawsuit against Oxford Nanopore in March, alleging that the firm infringes on a patent PacBio holds related to single-molecule sequencing.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.